Tomsk researchers develop a radiopharmaceutical based on gamma aluminum oxide

The scientists at the Cancer Research Institute of the Tomsk National Research Medical Center of the Russian Academy of Sciences are developing a drug for diagnosis of cancer metastases in sentinel lymph nodes, which will be five times more active than its foreign analogs.

“The currently used radiopharmaceuticals have various chemical structure but, in general, they are labeled nanocolloids. All of them accumulate in small amounts (one to two percent) in the sentinel node but, sometimes, they manage to pass through a sentinel node and accumulate in the adjacent one. In addition, none of these drugs is registered in Russia,” said Vladimir Chernov, the Deputy Director for Science and Innovation at the Cancer Research Institute of the Tomsk National Research Medical Center of the Russian Academy of Sciences.

The scientists in Tomsk have proposed a non-standard solution to use the gamma aluminum oxide for the diagnosis.

“In the first studies, it remained at the injection area without migrating through the lymphatic vessels,” said Vladimir Chernov. “To improve the lymphotrophy, we coated the gamma aluminum oxide nanoparticles with an organic shell. Now, when the nanoparticles get into the sentinel lymph node, the shell is absorbed by the macrophages, and gamma aluminum oxide acquires its initial properties and thereafter is firmly fixed in the node. Moreover, we obtained the accumulation that is five times higher than in case of the foreign analogs. On the one hand, the created drug is very simple but, on the other hand, it is very effective.”

Isaltis Banner